3'-nitrobenzylideneacetoacetic acid ethyl ester | 70076-42-5

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: 3'-nitrobenzylideneacetoacetic acid ethyl ester
• 英文别名: 3-nitrobenzylidene acetoacetic acid ethyl ester；ethyl 3'-nitrobenzylideneacetoacetate；ethyl 3-nitrobenzylidene acetoacetate；3-Nitrobenzylideneacetoacetic acid ethyl ester；ethyl 5-(3-nitrophenyl)-3-oxopent-4-enoate
• CAS: 70076-42-5
• 化学式: C₁₃H₁₃NO₅
• 分子量: 263.25
• InChiKey: GASYWQNGISZARS-UHFFFAOYSA-N

物化性质

• 熔点：
  208 °C
• 沸点：
  415.7±35.0 °C(Predicted)
• 密度：
  1.260±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  89.2
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3'-nitrobenzylideneacetoacetic acid ethyl ester 、 乙酰乙酸烯丙酯 在 氨 作用下， 以 乙醇 为溶剂， 以55%的产率得到2,6-dimethyl-4-(3'-nitrophenyl)1,4-dihydropyridine-3,5-dicarboxylic acid 3-ethyl ester-5-allyl ester
  参考文献：
  名称：

  Pharmaceutical compositions containing unsymmetrical esters of

  摘要：

  含有不对称酯化的1,4-二氢吡啶-3,5-二羧酸的药物组合物作为活性成分，并使用方法。所述成分是在二氢吡啶核的4位被苯基取代的不对称1,4-二氢吡啶-3,5-二羧酸酯，该苯基含有至少一个硝基、氰基、叠氮基、烷基硫醚或烷基磺酰基取代基。这些组合物具有心血管活性，可用于促进冠状血管扩张，并且在治疗高血压方面具有用途。

  公开号：

  US03932645A1
• 作为产物：
  描述：

  N,N'-羰基二咪唑 、 间硝基肉桂酸 、 氯化镁 、 钾 、 丙二酸单乙酯 在 盐酸 、 碳酸氢钠 、 氯化钠 、 Sodium sulfate-III 、 silica gel 、 ethyl acetate n-hexane 作用下， 以 四氢呋喃 、 乙酸乙酯 为溶剂， 反应 2.5h， 以to obtain ethyl 5-(3-nitrophenyl)-3-oxo-4-pentenoate (4.3 g, 16.3 mmol, 63%) as pale yellow prisms的产率得到3'-nitrobenzylideneacetoacetic acid ethyl ester
  参考文献：
  名称：

  Benzoxazepinones and their use as squalene synthase inhibitors

  摘要：

  公开了一种化合物，其化学式表示为[I]：1，其中R1是可选择的1-羧基乙基基团，可选择的烷基-磺酰基团，可选择的（羧基-环烷基）-烷基基团，-X1-X2-Ar-X3-X4-COOH（其中X1和X4是键或烷基链，X2和X3是键，-O-，-S-，Ar是双价芳香族基等），R2是烷基，可选择地取代烷酰氧基和/或羟基，R3是烷基，W是卤素原子等，或其盐。该化合物具有降低胆固醇和甘油三酯的活性，可用于预防和/或治疗高脂血症。

  公开号：

  US20030078251A1

文献信息

• Use of 1,6-naphthyridinone derivatives in treating pulmonary thrombosis
  申请人：Godecke Aktiengesellschaft

  公开号：US04698341A1

  公开（公告）日：1987-10-06

  New 1,6-naphthyridinone derivatives of the formula I ##STR1## are herein described wherein R.sup.1 represents an unsubstituted or substituted aromatic or heteroaromatic ring; R.sup.2 is hydrogen, a straight-chained or branched alkyl, alkoxyalkyl, or a substituted or unsubstituted aminoalkyl group with up to ten carbon atoms; R.sup.3 is hydrogen, a straight-chained or branched alkyl group, or an alkoxycarbonyl radical with up to four carbon atoms; R.sup.4 is hydrogen, or a morpholinoethyl group; R.sup.5 is a straight-chained or branched alkyl group with up to four carbon atoms, or an amino group; and R.sup.6 is a carboxyl group, or an alkyl- or alkyloxyalkyl carbonyl radical, containing up to 12 carbon atoms and optionally interrupted by an oxygen, sulphur, or nitrogen atom; as well as optionally the pharmacologically acceptable salts thereof; processes for the preparation of these derivatives and their use in the control of vascular diseases.

  本文介绍了式I的新型1,6-萘啶酮衍生物，其中R.sup.1代表未取代或取代的芳香或杂芳环；R.sup.2为氢，直链或支链烷基，烷氧基烷基，或取代或未取代的氨基烷基，其碳原子数不超过十个；R.sup.3为氢，直链或支链烷基，或具有最多四个碳原子的烷氧羰基基团；R.sup.4为氢或吗啉基乙基基团；R.sup.5为具有最多四个碳原子的直链或支链烷基或氨基；R.sup.6为羧基或含有最多12个碳原子的烷基或烷氧基烷基羰基基团，可选地被氧、硫或氮原子中断；以及它们的药学上可接受的盐；制备这些衍生物的方法以及它们在控制血管疾病中的应用。
• 1,2-Pentamethylene-1,4-dihydropyridine derivatives
  申请人：Bayer Aktiengesellschaft

  公开号：US03951988A1

  公开（公告）日：1976-04-20

  1,4-Dihydropyridines bearing carbonyl functions in the 3- and 5-positions, being optionally substituted by lower alkyl in the 6-position, being substituted in the 4-position by lower alkyl, phenyl, substituted phenyl or a heterocyclic group, and being fused through the 1- and 2-positions to a five, six or seven membered cycloalkyl ring, one methylene group of which can be replaced by sulfur, oxygen imino or alkylimino, are antihypertensive agents and coronary vessel dilators. The compounds, of which 6-methyl-4-(3-nitrophenyl)-1,2-pentamethylene-1,4-dihydropyridine-3,5-dica rboxylic acid 3,5-diethyl ester is a representative embodiment, are prepared through condensation of an ylideneacetoacetic acid ester and a cyclic enamino carbonyl derivative.

  3-和5-位带有羰基功能的1,4-二氢吡啶，可在6位被低烷基取代，在4位被低烷基、苯基、取代苯基或杂环基取代，并通过1-和2-位与五、六或七元环烷基环融合，其中一个亚甲基可以被硫、氧、亚胺或烷基亚胺取代，是降压剂和冠状血管扩张剂。这些化合物，其中6-甲基-4-(3-硝基苯基)-1,2-戊亚甲基-1,4-二氢吡啶-3,5-二羧酸3,5-二乙酯是一个典型实施例，是通过酰乙酸酯和环烯酮羰基衍生物的缩合反应制备的。
• Tetrahydroimidazolo[1,2-a]pyridine derivatives
  申请人：Bayer Aktiengesellschaft

  公开号：US03935220A1

  公开（公告）日：1976-01-27

  1,4-Dihydropyridines bearing carbonyl functions in the 3- and 5-positions, being optionally substituted by lower alkyl in the 6-position, being substituted in the 4-position by lower alkyl, phenyl, substituted phenyl or a heterocyclic group, and being fused through the 1- and 2-positions to a five, six or seven membered cycloalkyl ring, one methylene group of which can be replaced by sulfur, oxygen imino or alkylimino, are antihypertensive agents and coronary vessel dilators. The compounds, of which 6-methyl-4-(3-nitrophenyl)-1,2-pentamethylene-1,4-dihydropyridine-3,5-dica rboxylic acid 3,5-diethyl ester is a representative embodiment, are prepared through condensation of an ylideneacetoacetic acid ester and a cyclic enamino carbonyl derivative.

  3-和5-位带有羰基功能的1,4-二氢吡啶，6-位可选择性地被低碳基取代，4-位被低碳基、苯基、取代苯基或杂环基所取代，并通过1-和2-位融合到五、六或七元环烷基环上，其中一个亚甲基可以被硫、氧、亚氨基或烷基亚氨基所取代，是抗高血压药和冠状血管扩张剂。这些化合物，其中6-甲基-4-(3-硝基苯基)-1,2-戊亚甲基-1,4-二氢吡啶-3,5-二羧酸3,5-二乙酯是一个代表性实施例，是通过酰乙酰酸酯和环状烯氨酮羰基衍生物的缩合制备的。
• Pentahydroqunolizine derivatives
  申请人：Bayer Aktiengesellschaft

  公开号：US03948923A1

  公开（公告）日：1976-04-06

  1,4-Dihydropyridines bearing carbonyl functions in the 3- and 5-positions, being optionally substituted by lower alkyl in the 6-position, being substituted in the 4-position by lower alkyl, phenyl, substituted phenyl or a heterocyclic group, and being fused through the 1- and 2-positions to a five, six or seven membered cycloalkyl ring, one methylene group of which can be replaced by sulfur, oxygen imino or alkylimino, are anti-hypertensive agents and coronary vessel dilators. The compounds, of which 6-methyl-4-(3-nitrophenyl)-1,2-pentamethylene-1,4-dihydropridine-3,5-dicar boxylic acid 3,5-diethyl ester is a representative embodiment, are prepared through condensation of an ylideneacetoacetic acid ester and a cyclic enamino carbonyl derivative.

  3-和5-位带有羰基功能的1,4-二氢吡啶，6-位可选择性地被低烷基取代，4-位被低烷基、苯基、取代苯基或杂环基取代，通过1-和2-位与五、六或七元环环烷基融合，其中一个亚甲基可以被硫、氧、亚胺或烷基亚胺取代，是降压剂和冠状血管扩张剂。这些化合物通过酰乙酸乙酯和环状烯氨酮羰基衍生物的缩合反应制备而成，其中6-甲基-4-(3-硝基苯基)-1,2-戊亚甲基-1,4-二氢吡啶-3,5-二羧酸二乙酯是一种代表性的实施例。
• Tetrahydroindolizine derivatives
  申请人：Bayer Aktiengesellschaft

  公开号：US03951994A1

  公开（公告）日：1976-04-20

  1,4-Dihydropyridines bearing carbonyl functions in the 3- and 5-positions, being optionally substituted by lower alkyl in the 6-position, being substituted in the 4-position by lower alkyl, phenyl, substituted phenyl or a heterocyclic group, and being fused through the 1- and 2-positions to a five, six or seven membered cycloalkyl ring, one methylene group of which can be replaced by sulfur, oxygen imino or alkylimino, are antihypertensive agents and coronary vessel dilators. The compounds, of which 6-methyl-4-(3-nitrophenyl)-1,2-pentamethylene-1,4-dihydropyridine-3,5-dica rboxylic acid 3,5-diethyl ester is a representative embodiment, are prepared through condensation of an ylideneacetoacetic acid ester and a cyclic enamino carbonyl derivative.

  3-和5-位带有羰基功能的1,4-二氢吡啶，可在6-位被低烷基取代，4-位被低烷基、苯基、取代苯基或杂环基取代，并通过1-和2-位融合到五、六或七元环环烷基环上，其中一个亚甲基可以被硫、氧、亚氨基或烷基亚氨基替换，是降压剂和冠状血管扩张剂。这些化合物的代表性实施例是6-甲基-4-(3-硝基苯基)-1,2-戊亚甲基-1,4-二氢吡啶-3,5-二羧酸3,5-二乙酯，通过酰乙酰乙酸酯和环状烯酰亚胺羰基衍生物的缩合制备。